
Biopharma CEOs assess the road ahead in 2026
After a turbulent 2025, the biopharma industry is heading into the new year with major questions still unresolved.
A tough biotech investing environment, aggressive direct-to-consumer drug marketing and sweeping U.S. policy changes reshaped the landscape last year. Many of those pressures are expected to persist into 2026, even as early signs point to a thaw in venture capital. At the same time, the industry is testing whether DTC drug sales can meaningfully affect pricing for patients and whether broad manufacturing onshoring goals can realistically apply to advanced therapies like cell and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.